NHS Scotland has adopted the UK AMR National Action Plan Target 4b:

"by 2029, to achieve 70% of total use of antibiotics from the Access category across the human healthcare system."

Local guidelines are compiled and reviewed to ensure appropriate, safe empirical antibiotic therapy is recommended aiming to minimise impact on antimicrobial resistance as much as possible.

Antibiotics are now divided into Access, Watch and Reserve categories in order to promote antimicrobial stewardship in the NHS.

 

The AWaRe classification is as follows:

Category Explanation Examples (oral only)

ACCESS

First & second line for empirical treatment of common infection syndromes

Cause less toxicity.

Lower risk of C difficile infection

Less potential for selecting antimicrobial resistance.

AMOXICILLIN

CEFALEXIN

CO-TRIMOXAZOLE

DOXYCYCLINE

FLUCLOXACILLIN

FOSFOMYCIN

METRONIDAZOLE

NITROFURANTOIN

PENICILLIN V

PIVMECILLINAM

TRIMETHOPRIM

WATCH

Broader spectrum

Higher toxicity

Higher potential for resistance developing

Use should be carefully monitored

AZITHROMYCIN

CEFUROXIME

CIPROFLOXACIN

CLARITHROMYCIN

CLINDAMYCIN

CO-AMOXICLAV

LEVOFLOXACIN

LYMECYCLINE

MINOCYCLINE

MOXIFLOXACIN

RESERVE

"Last resort" antibiotics

Used for highly selected patients (severe/life-threatening infections due to multi-drug-resistant bacteria)

Usually on advice from Microbiology / Infectious disease only or if no other antibiotic options available (e.g on microbiology culture report)

LINEZOLID